Morgan Stanley Initiates Coverage on EIKN (NASDAQ:EIKN)

Analysts at Morgan Stanley started coverage on shares of EIKN (NASDAQ:EIKN) in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage set an “overweight” rating and a $32.00 price target on the stock. Morgan Stanley’s price target would suggest a potential upside of 132.22% from the stock’s previous close.

Several other research analysts have also recently commented on EIKN. Wedbush started coverage on shares of EIKN in a report on Thursday. They set an “underperform” rating and a $7.00 target price for the company. Bank of America initiated coverage on shares of EIKN in a research report on Monday. They set a “buy” rating and a $34.00 price target on the stock. Mizuho began coverage on EIKN in a report on Monday. They issued an “outperform” rating and a $26.00 price objective for the company. Finally, Wall Street Zen raised EIKN to a “hold” rating in a research report on Monday, February 16th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, EIKN currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.75.

EIKN Price Performance

NASDAQ:EIKN opened at $13.78 on Monday. EIKN has a twelve month low of $13.28 and a twelve month high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.